Drug Profile
HORA PDE6B
Alternative Names: AAV2/5-hPDE6B; CTx PDE6B; HORA-PDE6BLatest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Horama
- Developer Coave Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Retinitis pigmentosa
Most Recent Events
- 31 May 2023 Efficacy and adverse events data from phase I/II trial in Retinitis pigmentosa released by Coave Therapeutics
- 27 Sep 2022 Coave Therapeutics plans a pivotal trial for Retinitis pigmentosa (Coave Therapeutics pipeline, September 2022)
- 16 Sep 2021 Coave Therapeutics and Thea Open Innovation enters into an exclusive licensing, co-development and commercialisation agreement for the co-development and commercialisation of HORA PDE6b